CA2889286A1 - Methods for treating anemia - Google Patents
Methods for treating anemia Download PDFInfo
- Publication number
- CA2889286A1 CA2889286A1 CA2889286A CA2889286A CA2889286A1 CA 2889286 A1 CA2889286 A1 CA 2889286A1 CA 2889286 A CA2889286 A CA 2889286A CA 2889286 A CA2889286 A CA 2889286A CA 2889286 A1 CA2889286 A1 CA 2889286A1
- Authority
- CA
- Canada
- Prior art keywords
- gdf11
- seq
- actriia
- actriib
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718128P | 2012-10-24 | 2012-10-24 | |
| US61/718,128 | 2012-10-24 | ||
| PCT/US2013/066353 WO2014066487A2 (en) | 2012-10-24 | 2013-10-23 | Methods for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2889286A1 true CA2889286A1 (en) | 2014-05-01 |
Family
ID=50545463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889286A Abandoned CA2889286A1 (en) | 2012-10-24 | 2013-10-23 | Methods for treating anemia |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150266950A1 (enExample) |
| EP (2) | EP2911682A4 (enExample) |
| JP (3) | JP6401172B2 (enExample) |
| CN (3) | CN112957462A (enExample) |
| AU (4) | AU2013334660B2 (enExample) |
| CA (1) | CA2889286A1 (enExample) |
| HK (1) | HK1214504A1 (enExample) |
| NZ (1) | NZ747350A (enExample) |
| WO (1) | WO2014066487A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA015105B1 (ru) | 2005-11-23 | 2011-06-30 | Акселерон Фарма Инк. | Антагонисты активина - actriia и их применение для стимулирования роста кости |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN107050424A (zh) | 2007-02-01 | 2017-08-18 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW202104248A (zh) | 2007-02-02 | 2021-02-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| TWI748373B (zh) | 2008-08-14 | 2021-12-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CA2764890A1 (en) | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| MX387164B (es) | 2009-06-12 | 2025-03-19 | Acceleron Pharma Inc | Proteínas de fusión actriib-fc truncadas. |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| EP3308796B1 (en) | 2012-11-02 | 2021-07-14 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
| KR102520970B1 (ko) * | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| BR112016029226A2 (pt) | 2014-06-13 | 2017-10-17 | Acceleron Pharma Inc | métodos e composições para o tratamento de úlceras |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| TWI773117B (zh) | 2014-12-03 | 2022-08-01 | 美商西建公司 | 活化素-actrii拮抗劑及治療貧血之用途 |
| US20180031579A1 (en) * | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| TWI814187B (zh) * | 2015-05-13 | 2023-09-01 | 美商西建公司 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| EP4190805A3 (en) | 2015-05-20 | 2023-08-16 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| MD3496739T2 (ro) | 2016-07-15 | 2021-09-30 | Acceleron Pharma Inc | Compoziții care cuprind polipeptide actriia pentru utilizarea în tratarea hipertensiunii pulmonare |
| PT3490582T (pt) | 2016-07-27 | 2024-08-21 | Acceleron Pharma Inc | Composições para utilização no tratamento da mielofibrose |
| CA3043180A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN107011430B (zh) * | 2017-04-07 | 2020-09-01 | 哈尔滨医科大学 | 一种具有生物学活性的截短的生长分化因子11及其制备方法 |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| AU2019206634B2 (en) | 2018-01-12 | 2024-06-27 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN113801880B (zh) * | 2021-07-27 | 2024-11-01 | 浙江大学 | 一种通过靶向敲除基因建立的早衰细胞模型及其sgRNA、构建方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| CA2194660C (en) * | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| US7795202B2 (en) | 1997-08-04 | 2010-09-14 | Neurorepair, Inc. | Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a) |
| NZ528341A (en) * | 1998-07-28 | 2005-06-24 | Univ Johns Hopkins Med | Use of reagents that affect growth differentiation factor-11 (GDF-11) to treat chronic or acute renal disease |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7572763B2 (en) | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| EP2314617B1 (en) | 2004-07-23 | 2015-06-24 | Acceleron Pharma Inc. | ActRII receptor polypeptides |
| WO2006105359A2 (en) * | 2005-03-30 | 2006-10-05 | Wyeth | Methods for stimulating hair growth by administering bmps |
| US7612040B2 (en) * | 2005-07-01 | 2009-11-03 | Acceleron Pharma Inc. | Lefty polypeptides and derivatives thereof |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| NZ577847A (en) * | 2006-12-18 | 2012-06-29 | Acceleron Pharma Inc | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TW202104248A (zh) | 2007-02-02 | 2021-02-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| US8236751B2 (en) | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| AU2009262968A1 (en) * | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Antagonists of activin-ActRIIa and uses for increasing red blood cell levels |
| TWI748373B (zh) * | 2008-08-14 | 2021-12-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EP3838919A1 (en) * | 2009-08-13 | 2021-06-23 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| CN103298832A (zh) * | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
-
2013
- 2013-10-23 HK HK16102359.3A patent/HK1214504A1/zh unknown
- 2013-10-23 CN CN202011542063.1A patent/CN112957462A/zh active Pending
- 2013-10-23 NZ NZ747350A patent/NZ747350A/en unknown
- 2013-10-23 CN CN202011541918.9A patent/CN112933223A/zh active Pending
- 2013-10-23 CN CN201380067832.9A patent/CN104981250A/zh active Pending
- 2013-10-23 AU AU2013334660A patent/AU2013334660B2/en active Active
- 2013-10-23 US US14/438,127 patent/US20150266950A1/en not_active Abandoned
- 2013-10-23 EP EP13849960.3A patent/EP2911682A4/en not_active Withdrawn
- 2013-10-23 CA CA2889286A patent/CA2889286A1/en not_active Abandoned
- 2013-10-23 EP EP19151143.5A patent/EP3527219A1/en not_active Withdrawn
- 2013-10-23 WO PCT/US2013/066353 patent/WO2014066487A2/en not_active Ceased
- 2013-10-23 JP JP2015539751A patent/JP6401172B2/ja active Active
-
2018
- 2018-07-12 JP JP2018131952A patent/JP2018184430A/ja active Pending
- 2018-11-02 AU AU2018256635A patent/AU2018256635A1/en not_active Abandoned
-
2020
- 2020-05-15 AU AU2020203198A patent/AU2020203198B2/en active Active
- 2020-06-24 JP JP2020108654A patent/JP2020183390A/ja not_active Withdrawn
-
2022
- 2022-03-21 AU AU2022201923A patent/AU2022201923A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016503398A (ja) | 2016-02-04 |
| AU2022201923A1 (en) | 2022-04-14 |
| NZ747350A (en) | 2020-07-31 |
| JP6401172B2 (ja) | 2018-10-10 |
| HK1214504A1 (zh) | 2016-07-29 |
| AU2020203198A1 (en) | 2020-06-11 |
| AU2018256635A1 (en) | 2018-11-22 |
| JP2020183390A (ja) | 2020-11-12 |
| AU2013334660B2 (en) | 2018-08-09 |
| CN112957462A (zh) | 2021-06-15 |
| WO2014066487A3 (en) | 2014-06-19 |
| EP2911682A4 (en) | 2016-03-23 |
| EP2911682A2 (en) | 2015-09-02 |
| AU2020203198B2 (en) | 2021-12-23 |
| US20150266950A1 (en) | 2015-09-24 |
| CN112933223A (zh) | 2021-06-11 |
| AU2013334660A1 (en) | 2015-05-14 |
| JP2018184430A (ja) | 2018-11-22 |
| CN104981250A (zh) | 2015-10-14 |
| WO2014066487A2 (en) | 2014-05-01 |
| EP3527219A1 (en) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021236465B2 (en) | Biomarker for use in treating anemia | |
| US20150266950A1 (en) | Methods for treating anemia | |
| AU2021212084B2 (en) | Activin-ActRII antagonists and uses for treating anemia | |
| US10195249B2 (en) | Activin-ActRII antagonists and uses for treating bone and other disorders | |
| HK40012688A (en) | Methods for treating anemia | |
| HK40023193A (en) | Biomarker for use in treating anemia | |
| HK1213948B (en) | Biomarker for use in treating anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181003 |
|
| EEER | Examination request |
Effective date: 20181003 |
|
| EEER | Examination request |
Effective date: 20181003 |
|
| EEER | Examination request |
Effective date: 20181003 |
|
| EEER | Examination request |
Effective date: 20181003 |
|
| FZDE | Discontinued |
Effective date: 20240318 |